211 related articles for article (PubMed ID: 21386634)
21. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.
Yao JC; Phan AT; Jehl V; Shah G; Meric-Bernstam F
Cancer Res; 2013 Mar; 73(5):1449-53. PubMed ID: 23436795
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
Bisht S; Feldmann G; Brossart P
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
[TBL] [Abstract][Full Text] [Related]
23. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Raymond E; Ruszniewski P
Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
[No Abstract] [Full Text] [Related]
24. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
26. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Mateo J; Heymach JV; Zurita AJ
Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
[TBL] [Abstract][Full Text] [Related]
27. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.
Ito T; Okusaka T; Ikeda M; Igarashi H; Morizane C; Nakachi K; Tajima T; Kasuga A; Fujita Y; Furuse J
Jpn J Clin Oncol; 2012 Oct; 42(10):903-11. PubMed ID: 22859827
[TBL] [Abstract][Full Text] [Related]
28. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Ito T; Igarashi H; Jensen RT; Takayanagi R
Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
[No Abstract] [Full Text] [Related]
29. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
30. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
31. The genetics of neuroendocrine tumors.
Öberg K
Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
[TBL] [Abstract][Full Text] [Related]
32. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Naraev BG; Strosberg JR; Halfdanarson TR
Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
[TBL] [Abstract][Full Text] [Related]
33. Recent studies show promise for treating rare pancreatic tumors.
Peres J
J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
[No Abstract] [Full Text] [Related]
34. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
35. [Erlotinib, sunitinib, and everolimus].
Takahashi M
Nihon Rinsho; 2015 Mar; 73 Suppl 3():409-13. PubMed ID: 25857058
[No Abstract] [Full Text] [Related]
36. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
37. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
38. [Targeted therapies, prognostic and predictive factors in endocrine oncology].
Hescot S; Baudin E; Borson-Chazot F; Lombès M
Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S13-22. PubMed ID: 24356287
[TBL] [Abstract][Full Text] [Related]
39. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic neuroendocrine tumors: does chemotherapy work?
Tejani MA; Saif MW
JOP; 2014 Mar; 15(2):132-4. PubMed ID: 24618436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]